Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Wednesday, February 14, 2024
For patients with nonmetastatic breast carcinoma in the United States, the online prognostication tool PREDICT may be used to accurately forecast rates of overall survival, according to a retrospective study published in JNCCN–Journal of the National Comprehensive Cancer Network. These findings suggest the clinical benefit of this novel tool in decision-making and estimating clinical risks in this patient population, explained Alberto J. Montero, MD, MBA, of University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, and colleagues.
From 2004 to 2012, a total of 708,652 women with unilateral breast cancer were recruited for the study. All patients were required to have at least 5 years of follow-up clinical assessment. Demographic information was collected for further analysis. Using the PREDICT model, prognostic scores were calculated for all patients.
The study findings revealed overall survival rates of 89.7% and 78.7% at the 5-year and 10-year intervals, respectively, for the actual population. When the PREDICT model was used, the 5- and 10-year overall survival rates were forecast at 88.3% and 73.8%, respectively. Of note, when patients had an increased Charlson-Deyo Comorbidity Score, the PREDICT model overestimated their rate of overall survival.
Furthermore, in a subset analysis examining patients who were diagnosed with breast carcinoma after 2010, the observed 5-year survival was documented as 90.8%; the PREDICT model calculated a 5-year survival rate of 88.9% in this patient population. Moreover, an additional subset analysis performed in patients who had HER2-negative disease or whose HER2 status was unknown revealed an observed 5-year overall survival rate of 89.0%, and the PREDICT model calculated this overall survival rate as 88.6%.
Disclosure: The study authors reported no conflicts of interest.
JNCCN–Journal of the National Comprehensive Cancer Network
JNCCN Spotlights
